COMMUNIQUÉS West-GlobeNewswire

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026
09/03/2026
Lyon (France), March 9 , 202 6 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The [...]
Valneva publiera ses résultats financiers consolidés 2025 le 18 mars 2026
09/03/2026
Lyon (France), le 9 mars 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA, société spécialisée dans les vaccins, a annoncé aujourd'hui qu’elle publiera ses résultats financiers pour l’exercice 2025 le mercredi 18 [...]
Hydration Room Opens in San Francisco’s Cow Hollow, Introducing Nurse-Administered, Medically Supervised IV Therapy Designed for Sustained Performance and Recovery
09/03/2026
New Union Street clinic delivers personalized hydration, immunity and performance support designed for sustained energy and resilience SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Hydration Room , a leading [...]
Surgery Partners, Inc. to Present at Upcoming Investor Conference
09/03/2026
BRENTWOOD, Tenn., March 09, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), is scheduled to meet with investors at the Barclays 28 th Annual Global Healthcare [...]
Zealand Pharma to participate in upcoming investor conferences in March 2026
09/03/2026
Press release – No. 5 / 2026 Zealand Pharma to participate in upcoming investor conferences in March 2026 Copenhagen, Denmark, March 9, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology [...]
CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
09/03/2026
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3 in Q3 2026 In the fourth paragraph, we are replacing milligrams with micrograms . The corrected press release follows. CARMEL, Ind., March 09, [...]
Glaucoma Research Foundation and Alcon Partner to Expand Access to Trusted Glaucoma Education
09/03/2026
New English and Spanish editions of Understanding and Living with Glaucoma and first-ever Spanish audiobook aim to reach high-risk Hispanic communities Resources will be available during Glaucoma Awareness Week [...]
Transactions in Connection with Share Buy-back Program
09/03/2026
Company Announcement COPENHAGEN, Denmark; March 9, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum [...]
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
09/03/2026
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • [...]
HNL Lab Medicine’s Career Connections Program Builds the Next Generation of Clinical Laboratory Professionals
09/03/2026
ALLENTOWN, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine is helping address the national shortage of clinical laboratory professionals through its Career Connections program, a hands-on initiative that [...]
CenTrak Showcases Next Generation of AI-Enhanced Location Intelligence Platform at HIMSS 2026
09/03/2026
New AI-powered insights and platform innovations expand how healthcare organizations use real-time location data to improve safety, streamline operations, and maximize RTLS value NEWTOWN, Pa., March 09, 2026 (GLOBE [...]
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
09/03/2026
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured across oral and [...]
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and [...]
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
09/03/2026
Toronto, ON, March 09, 2026 (GLOBE NEWSWIRE) -- Cloudcure, a specialized health platform dedicated to improving metabolic health through evidence-based, personalized medicine, has announced the launch of its new weight [...]
SafeSpace Global Opens Nashville Office, Builds Operational Infrastructure to Support Revenue Growth
09/03/2026
Company Transitions from Remote Operations to Physical Facility; Plans Technology Demonstration Center, Expanded Workforce and Investor Events NASHVILLE, TN., March 09, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global [...]
AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK ), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially [...]
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
09/03/2026
HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical models of pancreatic [...]
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
09/03/2026
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3 β plus RAS inhibition [...]

Pages